Therapeutics

Results from our recent poll indicate a mixed bag of responses from ophthalmologists.

The deal adds pharmaceutical research and development capabilities and further expertise for future product pipeline. It also expands Alcon’s presence in the $20 billion global ophthalmic pharmaceutical category.

A recent study showed that only 6% of practicing ophthalmologists in the US identify as an underrepresented minority.

Ophthalmologists have learned to optimize their use of traditional anti-VEGF therapies and are now incorporating newer therapies like brolucizumab for managing retinal diseases, and in the not-so-distant future they can look forward to gaining familiarity with faricimab and using a new delivery system for ranibizumab.

Viatris intends to acquire Oyster Point Pharma as the foundation of its new ophthalmology franchise, recognizing its uniquely talented team, the strength of Tyrvaya nasal spray and its ophthalmology pipeline.

Jay S. Duker, MD, chief operating officer of EyePoint Pharmaceuticals, highlights the Phase 1 and Phase 2 DAVIO clinical trials for EYP-1901 in wet age-related macular degeneration. The company also announced the first patient has been dosed in the Phase 2 PAVIA trial of EYP-1901 for nonproliferative diabetic retinopathy.

The survey addressed topics that would facilitate a better understanding of the awareness of retina specialists regarding this relative new form of treatment in ophthalmology.

Nicox reports that daily dosing of NCX 470 0.1% met the primary efficacy objective of demonstrating non-inferiority to latanoprost 0.005%.

This post-hoc analysis was performed to evaluate immunogenicity over the long term.

First-in-human biologic stent in ophthalmology is a conforming implant material, i.e., a soft, scleral wall compliant bio-tissue to structurally reinforce the cyclodialysis cleft opening.

The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the two groups.

According to Rishi P. Singh, MD, family history and lifestyle are key in the development of geographic atrophy.

Regeneron announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.

Retina indications for which ranibizumab-eqrn is interchangeable include neovascular (wet) age-related macular degeneration; macular edema following retinal vein occlusion; diabetic macular edema; diabetic retinopathy, and myopic choroidal neovascularization.

A novel eye drop under development may provide neuroprotection to the retinal ganglion cells.

According to the company, pegcetacoplan is an investigational, targeted C3 therapy for the treatment of geographic atrophy secondary to age-related macular degeneration.

Cynthia Matossian, MD, FACS, ABES, explains why eye care professionals should oversee the selection and use of artificial tears for patients with dry eye.

In the TENAYA and LUCERNE studies, more than 60% of faricimab patients could be treated every 4 months at 2 years, an increase from 45% at year 1. Study results are being presented at the American Society of Retina Specialists 2022 annual meeting in New York.

Kala Pharmaceuticals Inc. announced that it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was first announced in May.

Researchers believe this may be the first report of the use of topical brimonidine gel for the treatment of eyelid ptosis associated with cosmetic use of botulinum toxin.

As dexamethasone adds indications, a study confirms efficacy of punctal occlusion for allergic conjunctivitis.

In a paper, investigators identified strategies used by patients to reduce the cost of therapy and its impact on adherence to treatment Patients may be reluctant to disclose challenges regarding adherence to dry eye disease therapy, as well as fears of worsening quality of life.

Aurion noted that its first candidate is a cell therapy for the treatment of corneal edema secondary to endothelial dysfunction.

TP-03 met the primary and all secondary endpoints, effectively resolved Demodex blepharitis and was well-tolerated with no serious treatment-related adverse events. 56% of patients on TP-03 achieved the primary endpoint of complete collarette cure.

According to researchers at the University of California, Irvine, base editing may provide long-lasting retinal protection and prevent vision deterioration in patients with inherited retinal degeneration, specifically in Leber congenital amaurosis patients.

According to the company, the VIRGO trial evaluated the safety and efficacy of the investigational twice-daily administration of pilocarpine HCl ophthalmic solution 1.25% in adults with presbyopia. The trial met its primary efficacy endpoint, the company noted.

Approval is based on year 1 data from the Phase III KESTREL and KITE trials investigating brolucizumab 6 mg versus aflibercept 2 mg in DME patients.

April is Presbyopia Awareness Month. Brieann K. Adair, OD, of NYU Langone Health, speaks with Ophthalmology Times’ Sheryl Stevenson about the importance of Presbyopia awareness, treatment options and more.

If the BLA is approved, the company could receive 12 years of marketing exclusivity for an FDA-approved alternative for the most frequently used anti-VEGF treatment in wet AMD patients in the United States.

A separate analysis will be presented at the American Academy of Neurology 2022 Annual Meeting, showing that UPLIZNA reduced pan associated with NMOSD over 3 years.